Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Accurate evaluation of tumor boundaries in breast-conserving surgery is closely associated with reducing the second operation of patients. Meanwhile, accurately assessing sentinel lymph node (SLN) metastasis is crucial for determining the extent of axillary lymph node dissection (ALND) and minimizing complications. Near-infrared-II (NIR-II) fluorescence imaging using molecular agents has shown promise for in situ imaging during resection. However, very effective probes can be applied to clinical trials up to now, which limits the clinical application of fluorescence imaging. Here we developed a new technology that can quickly differentiation between cancer and para-cancer tissue as well as metastatic and normal sentinel lymph nodes(SLN). In brief, the fresh tissues were incubated with the probe immediately after intraoperative resection and imaged to identify the tumor area and distinguish the metastatic status of SLN. The accuracy of fluorescence imaging was confirmed by pathological diagnosis.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Adult patients between 18-75 years of age

• Female

• Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment

• Good operative candidate

• Subject capable of giving informed consent and participating in the process of consent

Locations
Other Locations
China
Yunnan Cancer Hospital
RECRUITING
Kunming
Contact Information
Primary
Yuanyuan Zhu,Doctor
18059766094@163.com
86+18059766094
Backup
Weiling Chen, Doctor
913208146@qq.com
86+13646039812
Time Frame
Start Date: 2024-09-01
Estimated Completion Date: 2025-12-25
Participants
Target number of participants: 40
Treatments
NIR-II probe incubation
The fresh excision breast tissues or SLN will be completely soaked in the NIR-II probe (i.e:ICG-POL6326) incubation solution (12.5,25,50,100 ug/mL) for1, 3, 5,7 or 10 min, followed by 5 min of rinsing with PBST buffer and drying with absorbent paper.The NIR-II fluorescence imaging will be then performed under the DPM NIR-II system. And the correlation between pathological characterization and fluorescent information will be further analyzed.
Related Therapeutic Areas
Sponsors
Collaborators: Xiang'an Hospital of Xiamen University
Leads: Yunnan Cancer Hospital

This content was sourced from clinicaltrials.gov